Oct. 21 at 7:40 PM
$FOLD continues to trade at lower multiples of projected sales versus 3 peers with like dollar forecasts & gross margin profiles.
FOLD is currently defending its patent rights against a generic pharma hoping to sell a biosimilar. We suspect this could be the reason why FOLD does not trade at like multiples versus its peers
$MIRM $TARS $KNSA
Again by peers we mean those commercial-stage bios with similar revenue projections & patent lives.
This is not investment advice.
$IBB